Spondyloarthritis (Spondyloarthropathy) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Spondyloarthritis (Spondyloarthropathy) – Drugs In Development, 2024 report and make more profitable business decisions.
Spondyloarthritis is an inflammatory arthritis characterized by inflammation of spine (spondylitis) and joints (arthritis). Lower back pain is its main symptom. Types of spondyloarthritis include ankylosing spondylitis, axial spondyloarthritis, enteropathic spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, and reactive arthritis. It is believed that spondyloarthritis may be developed through the interaction of genetic and environmental factors. Symptoms include back pain and stiffness, fatigue, painful swelling of the joints, and episodes of eye inflammation. It can be diagnosed with the help of blood tests identifying HLA-B27 (a gene variant that controls immune responses) and through imaging studies. Treatment options includes NSAIDS, DMARDS TNF inhibitors, IL-17A inhibitors, and other biologics, which are also used to treat peripheral spondyloarthritis.
The Spondyloarthritis (Spondyloarthropathy) drugs in development market research report provide comprehensive information on the therapeutics under development for Spondyloarthritis (Spondyloarthropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spondyloarthritis (Spondyloarthropathy) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Spondyloarthritis (Spondyloarthropathy) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Spondyloarthritis (Spondyloarthropathy) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Spondyloarthritis (Spondyloarthropathy) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Spondyloarthritis (Spondyloarthropathy) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAlma Bio Therapeutics
Boehringer Ingelheim International GmbH
Immunos Therapeutics AG
MRM Health NV
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Spondyloarthritis (Spondyloarthropathy) reports